FDA group model in R [Two-Stage / GS Designs]
Dear mittyri,
Dear zizou,
Thank you very much for your help!
I have checked proposed model formula in R's lm() versus SAS output of some old study report with unbalanced dataset.
I found perfect much here for group*treatment!
1. Analysis started as FDA Group Model 1:
F and P values for group:drug are exactly the same as obtained by SAS:
2. I've got same F and P values (at least for some of the effects) while proceeding to FDA Group Model 2 (or EMA's only model with all effects fixed), not mentioning exactly the same outputs for MSE/ Intra-subject CV and PE / 90%CIs :
SAS output:
Maybe lm() sometimes doing exactly the same as PROC GLM?
Regards, VStus
Dear zizou,
❝ The ANOVA type I is the same as in PHX, but PE and CIs are not. I'm in stuck....
Thank you very much for your help!
I have checked proposed model formula in R's lm() versus SAS output of some old study report with unbalanced dataset.
I found perfect much here for group*treatment!
1. Analysis started as FDA Group Model 1:
> anovadata <- lm(log(data2$Cmax)~group+seq+seq*group+subj%in%(seq)+prd%in%group+drug+drug*group, data=data2, na.action=na.exclude)
> anova(anovadata)
Analysis of Variance Table
Response: log(data2$Cmax)
Df Sum Sq Mean Sq F value Pr(>F)
group 1 0.12 0.120 1.23 0.272
seq 1 0.05 0.046 0.47 0.497
drug 1 0.18 0.182 1.87 0.177
group:seq 1 0.46 0.460 4.71 0.034 *
seq:subj 59 25.25 0.428 4.38 3e-08 ***
group:prd 2 0.33 0.164 1.68 0.195
group:drug 1 0.01 0.007 0.07 0.797
Residuals 59 5.76 0.098
> drop1(anovadata, test="F")
Single term deletions
Model:
log(data2$Cmax) ~ group + seq + seq * group + subj %in% (seq) +
prd %in% group + drug + drug * group
Df Sum of Sq RSS AIC F value Pr(>F)
<none> 5.76 -255
group:seq 0 0.00 5.76 -255
seq:subj 59 25.25 31.01 -161 4.38 3e-08 ***
group:prd 2 0.32 6.09 -252 1.64 0.2
group:drug 1 0.01 5.77 -256 0.07 0.8
F and P values for group:drug are exactly the same as obtained by SAS:
Param Source DF F Value P-value Model to be used:
lCmax Group*Treat 1 0.07 0.7966 N.S. Remove interaction
2. I've got same F and P values (at least for some of the effects) while proceeding to FDA Group Model 2 (or EMA's only model with all effects fixed), not mentioning exactly the same outputs for MSE/ Intra-subject CV and PE / 90%CIs :
> anovadata2 <- lm(log(data2$Cmax)~group+seq+seq*group+subj%in%(seq)+prd%in%group+drug, data=data2, na.action=na.exclude)
> drop1(anovadata2, test="F")
Single term deletions
Model:
log(data2$Cmax) ~ group + seq + seq * group + subj %in% (seq) +
prd %in% group + drug
Df Sum of Sq RSS AIC F value Pr(>F)
<none> 5.77 -256
drug 1 0.21 5.98 -254 2.15 0.15
group:seq 0 0.00 5.77 -256
seq:subj 59 25.25 31.02 -163 4.45 1.8e-08 ***
group:prd 2 0.33 6.10 -254 1.71 0.19
SAS output:
Param Effect DF F Value P-value
lCmax Group 1 0.21 0.6475
lCmax Seq 1 0.31 0.5822
lCmax Group*Seq 1 1.08 0.3040
lCmax Treat 1 2.15 0.1476
lCmax Per(Group) 2 1.71 0.1896
lCmax Subj(Group*Seq) 59 4.45 <.0001
Maybe lm() sometimes doing exactly the same as PROC GLM?
Regards, VStus
Complete thread:
- Potvin C in the EU Helmut 2013-04-16 17:40 [Two-Stage / GS Designs]
- Potvin C in the EU ElMaestro 2013-04-17 02:31
- Potvin C in the EU Helmut 2013-04-17 12:23
- 2 Groups model FDA d_labes 2013-04-17 13:10
- 2 Groups model FDA Helmut 2013-04-17 16:37
- Group effects obsolete? d_labes 2013-04-18 09:55
- Group effects FDA/EMA Helmut 2013-04-19 14:34
- Group effects FDA/EMA mittyri 2014-08-21 15:34
- Group effects FDA/EMA ElMaestro 2014-08-21 17:31
- Group effects EMA mittyri 2014-10-01 11:25
- Group effects EMA ElMaestro 2014-10-01 11:31
- Group effects EMA Helmut 2014-10-01 13:24
- Group effects EMA VStus 2016-10-06 22:06
- Group effects EMA ElMaestro 2016-10-07 12:45
- Group effects EMA mittyri 2016-10-07 15:06
- Fixed effects model with Group term mittyri 2016-10-09 13:27
- Fixed effects model: changing the F, p values mittyri 2016-10-10 18:33
- Fixed effects model: changing the F, p values ElMaestro 2016-10-10 20:10
- Fixed effects model: changing the F, p values Helmut 2016-10-11 00:17
- Holy War of type III d_labes 2016-10-11 13:17
- Significance of Group effect in Russia: why the type III is so 'important' mittyri 2016-10-11 15:07
- Fixed effects model: changing the F, p values zizou 2016-10-11 01:06
- FDA group model in R mittyri 2016-10-11 13:43
- FDA group model in R ElMaestro 2016-10-12 01:07
- FDA group model in RVStus 2016-10-17 15:32
- FDA group model in R ElMaestro 2016-10-17 18:58
- FDA group model in R VStus 2016-10-20 13:57
- FDA group model in R ElMaestro 2016-10-17 18:58
- FDA group model in R mittyri 2016-10-11 13:43
- Fixed effects model: changing the F, p values ElMaestro 2016-10-10 20:10
- Fixed effects model with Group term VStus 2016-10-20 13:54
- Fixed effects model: changing the F, p values mittyri 2016-10-10 18:33
- Fixed effects model with Group term mittyri 2016-10-09 13:27
- Group effects EMA mittyri 2016-10-07 15:06
- Group effects EMA ElMaestro 2016-10-07 12:45
- Group effects EMA VStus 2016-10-06 22:06
- Group effects FDA/EMA zizou 2016-12-31 02:54
- Group effects FDA/EMA Helmut 2017-06-03 14:57
- Group effects EMA mittyri 2014-10-01 11:25
- Group effects FDA/EMA ElMaestro 2014-08-21 17:31
- Group effects FDA/EMA mittyri 2014-08-21 15:34
- Group effects FDA/EMA Helmut 2013-04-19 14:34
- 2 Groups model FDA hiren379 2013-08-22 14:32
- Homework Helmut 2013-08-23 11:53
- Group effects obsolete? d_labes 2013-04-18 09:55
- 2 Groups model FDA Helmut 2013-04-17 16:37
- 2 Groups model FDA d_labes 2013-04-17 13:10
- Potvin C in the EU Helmut 2013-04-17 12:23
- Potvin C in the EU ElMaestro 2013-04-17 02:31